

## Back to the future

## Adaptive management: what have we not to forget?

Birgitte Vrou Offersen Professor, PhD Dept Experimental Clinical Oncology Aarhus University Hospital Denmark






# No conflicts of interest



### Take home message 1

**Develop guidelines** 




#### The Danish Breast Cancer Group Radiotherapy Committee Guidelines









Birgitte V. Offersen <sup>a,\*</sup>, Liesbeth J. Boersma <sup>b</sup>, Carine Kirkove <sup>c</sup>, Sandra Hol <sup>d</sup>, Marianne C. Aznar <sup>e</sup>, Albert Biete Sola <sup>f</sup>, Youlia M. Kirova <sup>g</sup>, Jean-Philippe Pignol <sup>h</sup>, Vincent Remouchamps <sup>i</sup>, Karolien Verhoeven <sup>j</sup>, Caroline Weltens <sup>j</sup>, Meritxell Arenas <sup>k</sup>, Dorota Gabrys <sup>1</sup>, Neil Kopek <sup>m</sup>, Mechthild Krause <sup>n</sup>, Dan Lundstedt <sup>o</sup>, Tanja Marinko <sup>p</sup>, Angel Montero <sup>q</sup>, John Yarnold <sup>r</sup>, Philip Poortmans <sup>s</sup>

Radiotherapy and Oncology 118 (2016) 205-208




ESTRO breast cancer consensus guidelines

ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer, version  $1.1 \pm$ 

CrossMark


Link available on X @BOffersen 1 hour delineation guide for early breast cancer



Radiotherapy



#### Level 1 Rotter level 2 Level 3 level 4





### Take home message 2

Make sure to follow the guidelines

# FOLON THE GUIDELINE SUBJECTIVE



## How to initiate adaptive breast cancer RT? The DBCG RT Nation study

Physics and Imaging in Radiation Oncology 27 (2023) 100485



End-to-end framework for automated collection of large multicentre radiotherapy datasets demonstrated in a Danish Breast Cancer Group cohort

Lasse Refsgaard<sup>a,j</sup>, Emma Riis Skarsø<sup>b,j</sup>, Thomas Ravkilde<sup>c</sup>, Henrik Dahl Nissen<sup>d</sup>, Mikael Olsen<sup>e</sup>, Kristian Boye<sup>f</sup>, Kasper Lind Laursen<sup>g</sup>, Susanne Nørring Bekke<sup>h</sup>, Ebbe Laugaard Lorenzen<sup>i</sup>, Carsten Brink<sup>i</sup>, Lise Bech Jellesmark Thorsen<sup>a,c</sup>, Birgitte Vrou Offersen<sup>a, b, c</sup>, Stine Sofia Korreman<sup>b, c, j, \*</sup>

<sup>a</sup> Department of Experimental Clinical Oncology, Aarhus University Hospital, Denmark

- <sup>h</sup> Department of Oncology, Copenhagen University Hospital Herlev and Gentofte, Copenhagen, Denmark
- <sup>i</sup> Laboratory of Radiation Physics, Department of Oncology, Odense University Hospital, Odense, Denmark



Check for updates	

<sup>&</sup>lt;sup>b</sup> Danish Center for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark

<sup>&</sup>lt;sup>c</sup> Department of Oncology, Aarhus University Hospital, Aarhus, Denmark

<sup>&</sup>lt;sup>d</sup> Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Denmark


e Department of Oncology, Zealand University Hospital, Department of Clinical Oncology and Palliative Care, Næstved, Denmark

<sup>&</sup>lt;sup>f</sup> Department of Oncology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark

<sup>&</sup>lt;sup>8</sup> Department of Medical Physics, Aalborg University Hospital, Aalborg, Denmark

<sup>&</sup>lt;sup>j</sup> Department of Clinical Medicine, Aarhus University, Aarhus, Denmark


### Data flow for the end-to-end framework






### Change of guideline for fractionation

Jan 1, 2009: 48Gy/24fr → 50Gy/25fr Spring 2015: The DBCG Skagen trial 1 starts








Refsgaard L et al, manuscript in preparation

# Delineation of the internal mammary nodes

The volume of CTVn\_IMN declines from 2015 (ESTRO guideline) After 2014, higher and less variation in dose to CTVn\_IMN





Refsgaard L et al, manuscript in preparation



### Take home message 3

Develop future guidelines through clinical trials





# Inter-center variations in contouring and planning compromises in the DBCG Skagen trial 1

## EL Lorenzen<sup>1</sup>, MS Thomsen<sup>2</sup>, T Bechmann<sup>3</sup>, M Berg<sup>4</sup>, MH Nielsen<sup>5</sup>, HV Hansen<sup>6</sup>, K Boye<sup>6</sup>, T Lörincz<sup>7</sup>, I Jensen<sup>8</sup>, SA Al-Rawi<sup>9</sup>, MMB Nielsen<sup>9</sup>, LW Matthiessen<sup>10</sup>, K Andersen<sup>10</sup>, MR Jensen<sup>11</sup>, J Overgaard<sup>12</sup>, BV Offersen<sup>12</sup>

<sup>1</sup>Odense University Hospital, Laboratory of Radiation Physics, Odense, Denmark; <sup>2</sup>Aarhus University Hospital, Department of Medical Physics, Aarhus, Denmark; <sup>3</sup>Vejle Hospital, Department of Oncology, Vejle, Denmark; <sup>4</sup>Vejle Hospital, Department of Medical Physics, Vejle, Denmark; <sup>5</sup>Odense University Hospital, Department of Oncology, Odense, Denmark; <sup>6</sup>Rigshospitalet, Department of Oncology, Copenhagen, Denmark; <sup>7</sup>Aalborg University Hospital, Department of Oncology, Aalborg, Denmark; <sup>8</sup>Aalborg, Denmark; <sup>8</sup>Aalborg University Hospital, Department of Medical Physics, Aalborg, Denmark; <sup>9</sup>Zealand University Hospital, Department of Oncology and Palliative Care, Naestved, Denmark; <sup>10</sup>Herlev and Gentofte Hospital, Department of Oncology, Herlev, Denmark; <sup>11</sup>Rigshospitalet, Danish Breast Cancer Cooperative Group Secretariat, Copenhagen, Denmark; <sup>12</sup>Aarhus University Hospital, Department of Experimental Clinical Oncology, Aarhus, Denmark

# Background

DBCG Skagen trial 1: 40Gy/15fr- vs 50Gy/25fr RT in 2879 pN+ breast cancer patients

DICOM-data from the **seven Danish centers** stored at DCMcollab


Inter-center variation target and OAR:

- Contouring
- Doses














# Intra-centre variation in volume – low variation for most





































## Volume - heart




Humeral Head Greater Tuberosity Lesser Tuberosity Anatomical Neck

# Volume – heart and humeral head

**Guidelines works!** 


... when they exists





## Volume – CTV breast








# Volume – CTV breast and CTV chest wall

Skin-crop-margin Delineation differences? <u>Needs further investigation</u>







# Intra-centre variation in dose – pronounced for several ROI's

CTVn\_L1





dose [Gy] 40


Mean o


20


CTVn IMN















dose [Gy]

40










#### Hypo-fractionated




CTVp breast


CTVn\_L2

Mean dose [Gy] 30 30


25

Mean dose [Gy] 01







CTVn L1




25




25



Pulm ipsilat







Presented at ESTRO conference 2022

Pulm contralat

# Level 1 - humeral head









# Results so far

Intra-centre variation in delineation was limited for most ROI's

Some variation in doses, likely due to different clinical compromises

- Does this translate into different risk of recurrence and morbidity?
- Results from the RT QA of the DBCG Skagen trial 1 & DBCG RT Nation study → evidence based dose constraints for doses to targets and OAR using adaptive RT



Take home message 4: International collaboration



EST<u>RO</u>



Easy & fast access to current developments in different countries Possible to use same stratifications, cut-off values etc Hypotheses from your trial can be validated in another trial

 $\rightarrow$  Faster access to better treatment for patients



#### Adaptive management: what have we not to forget?

Big pressure towards new modern techniques (IMRT, VMAT)  $\rightarrow$  but what are the dose constraints for heart, lung, humeral head etc versus doses to targets when combined with modern systemic therapy?  $\rightarrow$  Phase IV studies/clinical trials can help us.

We must continue to develop RT through clinical studies and trials  $\rightarrow$  Every patient should be included in minimum one clinical trial

#### THANKS!



